You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
Mourad Tighiouart and André Rogatko
Vol. 25, No. 2 (May 2010), pp. 217-226
Published by: Institute of Mathematical Statistics
Stable URL: http://www.jstor.org/stable/41058942
Page Count: 10
You can always find the topics here!Topics: Dosage, Phase I clinical trials, Overdose, Experimentation, Clinical trials, Toxicity, Maximum tolerated dose, Computer software, Parametric models, Statism
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment efficacy. The dose sought is typically referred to as the maximum tolerated dose (MTD). Several statistical methodologies have been proposed to select the MTD in cancer phase I trials. In this manuscript, we focus on a Bayesian adaptive design, known as escalation with overdose control (EWOC). Several aspects of this design are discussed, including large sample properties of the sequence of doses selected in the trial, choice of prior distributions, and use of covariates. The methodology is exemplified with real-life examples of cancer phase I trials. In particular, we show in the recently completed ABR-217620 (naptumomab estafenatox) trial that omitting an important predictor of toxicity when dose assignments to cancer patients are determined results in a high percent of patients experiencing severe side effects and a significant proportion treated at sub-optimal doses.
Statistical Science © 2010 Institute of Mathematical Statistics